Drug Development in NASH: Accelerate Time To Market For GI Clinical Trials

We are a GI-focused CRO with proven in-depth GI-specific knowledge throughout the entire organization and finely tuned operational workflows developed by our industry-leading KOLs.

Watch our expert panel provide an overview of nonalcoholic steatohepatitis (NASH) including a review of the drug development landscape, imaging as a non-invasive measure in NASH Clinical Trials, and the role of histopathology and machine learning in NASH Clinical Trials. Featured presentations include:

– Overview of the Current and Evolving Drug Development Landscape in 2022
– The Role of Imaging as a Non-Invasive Measurement in NASH Clinical Trials
– The Role of Histopathology and Machine Learning in NASH Clinical Trials

Share the Post:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to our use of all cookies, however, you may visit “Cookies Setting” to provide a controlled consent.

Privacy Policy